C4 Therapeutics is preparing to launch a clinical trial testing its lead investigational therapy CFT7455 in multiple myeloma and other blood cancers. The U.S. Food and Drug Administration (FDA) approved the company’s application requesting a Phase 1/2a trial, which could open by mid-year. “With FDA clearance achieved, we are on track to advance CFT7455 into the clinic in the first half of 2021,” Andrew Hirsch, president and CEO of C4 Therapeutics, said in a press…

You must be logged in to read/download the full post.